scholarly journals Increasing incidence of metastatic prostate cancer in the United States (2004–2013)

2016 ◽  
Vol 19 (4) ◽  
pp. 395-397 ◽  
Author(s):  
A B Weiner ◽  
R S Matulewicz ◽  
S E Eggener ◽  
E M Schaeffer
Keyword(s):  
Prostate Cancer ◽  
United States ◽  
Metastatic Prostate Cancer ◽  
The United States

scholarly journals Rare Paravertebral and Skull Base Metastases in Prostate Cancer

2016 ◽  
Vol 9 (3) ◽  
pp. 738-746 ◽  
Author(s):  
Gbeminiyi Samuel ◽  
Amir Isbell ◽  
Onyekachi Ogbonna ◽  
Hasan Iftikhar ◽  
Susmita Sakruti ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
United States ◽  
Metastatic Prostate Cancer ◽  
Clinical Presentation ◽  
The United States ◽  
Unique Case ◽  
Skull Base Metastases ◽  
The Right ◽  
Upper Mediastinum ◽  
Paravertebral Mass

Prostate cancer is the most commonly diagnosed visceral cancer in the United States. A majority of cases exhibit an insidious course and nonaggressive tumor behavior. Prostate cancer can manifest as lesions which remain localized, regionally invading or metastasize to lymph nodes, bones, and lungs. Here, we report a unique case of metastatic prostate cancer to the right upper mediastinum, presenting as a paravertebral mass within 2 years of initial tissue diagnosis. Paravertebral spread has not been described for prostate cancer, and herein, we discuss the clinical presentation, diagnostic workup, and possible therapeutic options available in light of the literature.

PD03-07 THE IMPACT OF SOCIOECONOMIC STATUS, RACE, AND INSURANCE TYPE ON THE RISK OF NEWLY DIAGNOSED METASTATIC PROSTATE CANCER IN THE UNITED STATES

2017 ◽  
Vol 197 (4S) ◽  
Author(s):  
Adam Weiner ◽  
Richard Matulewicz ◽  
Jeffrey Tosoian ◽  
Joseph Feinglass ◽  
Edward Schaeffer
Keyword(s):  
Prostate Cancer ◽  
United States ◽  
Socioeconomic Status ◽  
Metastatic Prostate Cancer ◽  
The United States ◽  
Newly Diagnosed ◽  
Insurance Type ◽  
The Impact

scholarly journals Patterns of Care and Outcomes for Non-Metastatic Prostate Cancer in the United States: Results of the CancerMPact® Survey 2018

2021 ◽  
Vol Volume 13 ◽  
pp. 9127-9137
Author(s):  
Eloisa de Sá Moreira ◽  
David Robinson ◽  
Stephanie Hawthorne ◽  
Linda Zhao ◽  
Madelyn Hanson ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
United States ◽  
Metastatic Prostate Cancer ◽  
The United States ◽  
Patterns Of Care

scholarly journals Treatment Pattern and Outcomes with Systemic Therapy in Men with Metastatic Prostate Cancer in the Real-World Patients in the United States

Cancers ◽  
2021 ◽  
Vol 13 (19) ◽  
pp. 4951
Author(s):  
Umang Swami ◽  
Jennifer Anne Sinnott ◽  
Benjamin Haaland ◽  
Nicolas Sayegh ◽  
Taylor Ryan McFarland ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
United States ◽  
Real World ◽  
Comparative Effectiveness ◽  
Metastatic Prostate Cancer ◽  
Proportional Hazards Model ◽  
The United States ◽  
Cox Proportional Hazards Model ◽  
Real World Data ◽  
Hormonal Therapies

Background: Both novel hormonal therapies and docetaxel are approved for treatment of metastatic prostate cancer (mPC; in castration sensitive or refractory settings). Present knowledge gaps include lack of real-world data on treatment patterns in patients with newly diagnosed mPC, and comparative effectiveness of novel hormonal therapies (NHT) versus docetaxel after treatment with a prior NHT. Methods: Herein we extracted patient-level data from a large real-world database of patients with mPC in United States. Utilization of NHT or docetaxel for mPC and comparative effectiveness of an alternate NHT versus docetaxel after one prior NHT was evaluated. Comparative effectiveness was examined via Cox proportional hazards model with propensity score matching weights. Each patient’s propensity for treatment was modeled via random forest based on 22 factors potentially driving treatment selection. Results: The majority of patients (54%) received only androgen deprivation therapy for mPC. In patients treated with an NHT, alternate NHT was the most common next therapy and was associated with improved median overall survival over docetaxel (abiraterone followed by docetaxel vs. enzalutamide (8.7 vs. 15.6 months; adjusted hazards ratio; aHR 1.32; p = 0.009; and enzalutamide followed by docetaxel vs. abiraterone (9.7 vs. 13.2 months aHR 1.40; p = 0.009). Limitations of the study include retrospective design.

scholarly journals Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States

2018 ◽  
Vol 4 (1) ◽  
pp. 121-127 ◽  
Author(s):  
Scott P. Kelly ◽  
William F. Anderson ◽  
Philip S. Rosenberg ◽  
Michael B. Cook
Keyword(s):  
Prostate Cancer ◽  
United States ◽  
Metastatic Prostate Cancer ◽  
The United States ◽  
Incidence Rates

scholarly journals The effect of socioeconomic status, race, and insurance type on newly diagnosed metastatic prostate cancer in the United States (2004–2013)

2018 ◽  
Vol 36 (3) ◽  
pp. 91.e1-91.e6 ◽  
Author(s):  
Adam B. Weiner ◽  
Richard S. Matulewicz ◽  
Jeffrey J. Tosoian ◽  
Joseph M. Feinglass ◽  
Edward M. Schaeffer
Keyword(s):  
Prostate Cancer ◽  
United States ◽  
Socioeconomic Status ◽  
Metastatic Prostate Cancer ◽  
The United States ◽  
Newly Diagnosed ◽  
Insurance Type

scholarly journals Prostate-specific Antigen Screening and Recent Increases in Advanced Prostate Cancer

2020 ◽  
Author(s):  
Yaw A Nyame ◽  
Roman Gulati ◽  
Alex Tsodikov ◽  
John L Gore ◽  
Ruth Etzioni
Keyword(s):  
Prostate Cancer ◽  
United States ◽  
Prostate Specific Antigen ◽  
Advanced Prostate Cancer ◽  
Metastatic Prostate Cancer ◽  
Specific Antigen ◽  
The United States ◽  
Models Of Disease ◽  
Screening And Diagnosis

Abstract Recent studies show decreasing prostate-specific antigen utilization and increasing incidence of metastatic prostate cancer in the United States after national recommendations against screening in 2012. Yet whether the increasing incidence of metastatic prostate cancer is consistent in magnitude with the expected impact of decreased screening is unknown. We compared observed incidence of metastatic prostate cancer from the Surveillance, Epidemiology, and End Results program and published effects of continued historical screening and discontinued screening starting in 2013 projected by two models of disease natural history, screening, and diagnosis. The observed rate of new metastatic prostate cancer cases in 2017 was 44%-60% of the projected increase under discontinued screening relative to continued screening. Thus, the observed increase in incident metastatic prostate cancer is consistent with the expected impact of reduced screening. Although this comparison does not establish a causal relationship, it highlights the plausible role of decreased screening in the observed trend.

Association of reductions in PSA screening across states with increased metastatic prostate cancer in the United States.

2021 ◽  
Vol 39 (6_suppl) ◽  
pp. 228-228
Author(s):  
Vidit Sharma ◽  
Abhishek Venkataramana ◽  
W. Scott Comulada ◽  
Mark S. Litwin ◽  
Christopher Saigal
Keyword(s):  
Prostate Cancer ◽  
United States ◽  
Linear Regression ◽  
Regression Model ◽  
Random Effects ◽  
Linear Regression Model ◽  
Metastatic Prostate Cancer ◽  
The United States ◽  
Psa Screening ◽  
The Mean

228 Background: While PSA screening was found to reduce prostate cancer metastasis and mortality in a large European randomized trial, PSA screening has also resulted in over-treatment of prostate cancer with significant quality-of-life implications. As a result, the US Preventive Services Task Force (USPSTF) did not recommend PSA screening in 2008 and 2012. It is unknown if reductions in PSA screening were responsible for increased metastatic prostate cancer in the United States. We test this hypothesis by associating longitudinal variations across individual states in PSA screening with their incidence of metastatic prostate cancer at diagnosis from 2002 to 2016. Methods: Age-adjusted incidences of metastatic prostate cancer at diagnosis per 100,000 men were obtained from the North American Association of Central Cancer Registries in 2002 – 2016 for each state. Survey-weighted PSA screening estimates for each state were extracted from the Behavioral Risk Factor Surveillance System, which collects this information for men at least 40 years of age every 2 years from 2002 onward. PSA screening and metastasis data were collated as a multi-panel time series and then analyzed using a random-effects linear regression model with random effects at the state level. Results: There was significant variation between states in the percent of men age >40 years who reported ever receiving PSA screening (range 40.1% to 70.3%) and in the age-adjusted incidence of metastatic prostate cancer at diagnosis (range 3.3 to 14.3 per 100,000). From 2008 to 2016, the mean percentage of men screened decreased (61.8% to 50.5%) whereas the mean incidence of metastatic prostate cancer at diagnosis increased (6.4 to 9.0 per 100,000; Bonferroni adjusted p < 0.001 for both). A random-effects linear regression model demonstrated that longitudinal reductions across states in PSA screening were associated with increased metastatic prostate cancer (regression coefficient per 100,000 men: 14.9, 95% CI 12.3 – 17.5, p < 0.001). This indicated that states with larger declines in PSA screening had larger increases in the incidence of metastatic prostate cancer at diagnosis. Variation in PSA screening explained 27% of the longitudinal variation in metastatic prostate cancer within states. Conclusions: In the context of randomized trial data demonstrating a metastasis reduction with PSA screening, our study strengthens the epidemiologic evidence that reductions in PSA screening may explain some of the recent increase in metastatic prostate cancer at diagnosis in the United States. The trend of rising metastatic disease at diagnosis is a worrisome consequence that needs attention. Thus, we support shared-decision making policies, such as the 2018 USPSTF update, that may optimize PSA screening utilization to reduce the incidence of metastatic prostate cancer in the United States.

scholarly journals PCN345 PATTERNS OF CARE AND OUTCOMES FOR NON-METASTATIC PROSTATE CANCER IN THE UNITED STATES: RESULTS OF THE CANCERMPACT® SURVEY 2018

2020 ◽  
Vol 23 ◽  
pp. S85
Author(s):  
E. Moreira ◽  
O. Clark ◽  
D. Robinson ◽  
G. Kanas ◽  
C. Davis ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
United States ◽  
Metastatic Prostate Cancer ◽  
The United States ◽  
Patterns Of Care
Sign in / Sign up

Export Citation Format

Share Document